Description
Mevalonate is an intermediate in the mevalonate pathway of cholesterol synthesis.
1 It inhibits cell death induced by the HMG-CoA reductase inhibitor simvastatin in C2C12 myoblasts when used at concentrations ranging from 80 to 110 μM.
2 Mevalonate (500 μM) reverses decreases in proliferation induced by the HMG-CoA reductase inhibitor lovastatin in several colon cancer cell lines, including RKO and SW480 cells.
3 It increases lovastatin-induced decreases in the expression of the genes encoding Axin2, ectodermal-neural cortex 1 (ENC1), BCL2-like 1 (BCL2-L1), and cyclin D1 when used at a concentration of 500 μM. Mevalonate (50 μM) increases Rac1 protein levels, as well as increases Rac1 farnesylation induced by the arachidonic metabolite 15(S)-HETE in human dermal microvascular endothelial cells (HDMVECs).
4
References
1. Yazawa, H., Zimmermann, B., Asami, Y., et al. Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells J. Periodontol. 76(2),295-302(2005).
2. Moschetti, A., Dagda, R.K., and Ryan, R.O. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes Nanomedicine 37,102439(2021).
3. Gong, L., Xiao, Y., Xia, F., et al. The mevalonate coordinates energy input and cell proliferation Cell Death Dis. 10(4),327(2019).
4. Singh, N.K., Kundumani-Sridharan, V., and Rao, G.N. 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation Blood 118(20),5701-5712(2011).
